Page 1

DexTech Know - how in Translational Research DexTech Medical AB Interim report July 1 , 2021 - September 30 , 2021 By " Company " or " DexTech " is meant DexTech Medical AB with organization number 556664-6203 . Summary of the First Quarter ( 2021-07-01 - 2021-09-30 ) • Net sales amounted to MSEK 0,0 ( 0,0 ) • Operating profit / loss amounted to MSEK -0,9 ( -1,5 ) • Earnings per share * SEK -0,06 ( -0.10 ) • Cash and cash equivalents at the end of the period amounted to MSEK 3,0 ( 5,5 ) * Before and after dilution . Earnings per share : Profit for the period divided by the average number of shares 14,920,478 . For the comparison period , the average number of shares was 14,920,478 . Amounts in brackets refer to the corresponding period last year . CEO's comment There are significant similarities between skeletal metastases from mCRPC and multiple myeloma , such as growth site , bone degradation and stimulation from osteoclasts . The preclinical results regarding the DexTex drug candidate OsteoDex ( ODX ) effect on multiple myeloma announced on August 24 , 2021 are significant . Based on these facts , DexTech has begun planning a clinical proof of concept study ( short study showing the relevance of the drug to a limited number of patients ) . Multiple myeloma is a hematologic malignancy that occurs in plasma cells in the bone marrow , and like skeletal metastases from prostate cancer ( mCRPC ) , causes bone resorption . Multiple myeloma is incurable where several different drugs are used to slow the progression . The disease eventually becomes resistant to existing drugs . The treatments often have serious side effects . DexTech has shown in extensive preclinical studies conducted at Karolinska Institutet in Stockholm that OsteoDex has a very significant tumor cell killing effect demonstrated on different myeloma cell cultures . In summary , a potent cytotoxic effect is visible even at low OsteoDex concentrations . Efficacy at low concentration is an important result in in vitro testing and indicates possible efficacy in vivo ( in living organism ) . The observed cell - killing effect is superior to the compared substance , Melphalan , which is an old standard medicine for the treatment of multiple myeloma . The company sees OsteoDex as very promising for the treatment of multiple myeloma based on its mechanism of action along with mild side effects . A formal study protocol for clinical research is now being prepared . The study is planned to be conducted at approximately five hospital centers in Scandinavia and involve approximately 20 selected patients with multiple myeloma . The aim is for the study to provide proof of concept and thus further verify Osteodex's high value as a potential cancer drug . The global multiple myeloma market size is expected to grow to approximately USD 31 billion by 2026 , which is more than double the market size of CRPC . The financing of the MM study will be through a directed share issue . Details of the issue will be presented in November 2021. The preparatory work for the study is expected to be completed by the end of 2021 . Although the company's main track is ODX - CRPC , supplemented positive ODX - MM results will strengthen the possibilities for a favorable license agreement . The Company will not enter into a license agreement that does not reflect ODX's actual value . By showing ODX potential even against MM , ODX's value can be appreciated and lead to a favorable license agreement .